Arca
Skip to content

Cholangiocarcinoma

Drug research and approvals for cholangiocarcinoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 214 studies of cholangiocarcinoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 14 drug trials for it since 2013, FDA has 5 approved and 26 open orphan designations naming it, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 214
  • Trials authorized in Canada: 14
  • FDA orphan approvals: 5
  • EU medicines: 2

Recruiting Now

Newest start dates first, of 214 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 14; search them all in Canada trials
Jun 5, 2025A phase 1b/2, safety lead-in and dose-expansion, open label, multicenter trial investigating the safety, tolerability, and preliminary activity of ivosidenib…IVOSIDENIB / DURVALUMAB / CISPLATIN / GEMCITABINEServierOngoing
May 8, 2025Perioperative therapy with gemcitabine/cisplatin/nab-paclitaxel and rilvegostomig (azd2936) for patients with resectable intrahepatic cholangiocarcinoma (icca)…GEMCITABINE / CISPLATIN / ABRAXANE / RILVEGOSTOMIGUNIVERSITY HEALTH NETWORKOngoing
Feb 27, 2025Phase 2 study of futibatinib 20 mg and 16 mg in patients with advanced cholangiocarcinoma with fgfr2 fusions or rearrangementsFUTIBATINIB (TAS-120)Taiho OncologyOngoing
Dec 23, 2024A phase 1/2 study of a selective fgfr2/3 inhibitor, cgt4859, in patients with cholangiocarcinoma and other advanced solid tumors harboring fgfr2 and/or fgfr3…CGT4859COGENT BIOSCIENCES, INC.Closed
Jul 20, 2023A phase 2a, double-blind, placebo-controlled, multi-center, randomized study evaluating lsta1 when added to standard of care (soc) versus standard of care…CERTEPETIDE (LSTA1)LISATA THERAPEUTICS, INC.Closed
Jun 22, 2023A first-in-human study of highly selective fgfr2 inhibitor, rly-4008, in patients with intrahepatic cholangiocarcinoma (icc) and other advanced solid tumorsRLY-4008RELAY THERAPEUTICS, INC.Closed
Apr 14, 2022A study to evaluate the efficacy of propranolol in boosting immunotherapy in hepatocellular carcinoma, cholangiocarcinoma and pancreatic adenocarcinoma…TREMELIMUMAB / DURVALUMAB / PROPRANOLOLCROSS CANCER INSTITUTE - CANCER CARE ALBERTAOngoing
Oct 22, 2020A phase 3, open-label, randomized study of futibatinib versus gemcitabine-cisplatin chemotherapy as first-line treatment of patients with advanced…FUTIBATINIB (TAS-120) / GEMCITABINE / CISPLATINTaiho OncologyPending
Aug 16, 2019A phase 3 multicenter, open-label, randomized, controlled study of oral infigratinib versus gemcitabine with cisplatin in subjects with advanced/metastatic or…INFIGRATINIB (BGJ398)/ GEMCITABINE/ CISPLATINQED THERAPEUTICS, INC.Closed
Jun 12, 2019A multi-centre, open-label phase 2 study of trifluridine/tipiracil in previously treated cholangiocarcinoma (the mocha trial)TRIFLURIDINE-TIPIRACILSUNNYBROOK RESEARCH INSTITUTEClosed

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 31
Sep 23, 2026Lyrfigtutreatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth…Elevar Therapeutics, Inc.Approved
May 8, 2026Bizengritreatment of adults with advanced unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease…Partner Therapeutics, Inc.Approved
Sep 30, 2022LytgobiTreatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring…Taiho Oncology, Inc.Approved
Aug 25, 2021TibsovoTreatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1…Servier Pharmaceuticals LLCApproved
Apr 17, 2020PEMAZYREPEMAZYRE is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma…Incyte CorporationApproved
Mar 8, 2026antibody-drug conjugate (ADC) composed of the humanized…treatment of cholangiocarcinomaHangzhou Zhongmei Huadong Pharmaceutical Co., LtdDesignated
Nov 14, 2025antibody-drug conjugate (ADC) consisting of a humanized…treatment of cholangiocarcinomaOBI Pharma USA Inc.Designated
Dec 5, 2024butaselentreatment of cholangiocarcinomaShanghai Yuanxi Medicine Corp.Designated
Sep 17, 2024Chimeric virus with a double-stranded DNA genome comprised…treatment of cholangiocarcinomaImugene LimitedDesignated
Aug 21, 2024N-(4-(4-Amino-7-cyano-1-methyl-3-(4-((4-methylpyrimidin-2-yl…treatment of cholangiocarcinoma (CCA)3H (Suzhou) Pharmaceuticals Co., Ltd.Designated
Aug 5, 2024certepetidetreatment of cholangiocarcinomaLisata Therapeutics, IncDesignated
Aug 16, 2023N-[5-(2,3-Dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluor…Treatment of cholangiocarcinomaNuvectis Pharma, Inc.Designated
Jan 23, 2023recombinant human IL12/15-PDL1B HSV-1 oncolytic virus…Treatment of cholangiocarcinomaVirogin Biotech Canada LtdDesignated
Oct 19, 2022a humanized immunoglobulin IgG1 antibody with a kappa light…Treatment of CholangiocarcinomaZielBio IncorporatedDesignated
Oct 11, 2022N-(6-(2,6-dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-b]py…Treatment of cholangiocarcinoma3D Medicines (Beijing) Co., LtdDesignated

Medicines Authorised in the EU

Newest first
Jul 4, 2023LytgobifutibatinibTaiho Pharma Netherlands B.V.EMA ↗
Mar 26, 2021Pemazyrepemigatinib · orphanIncyte Biosciences Distribution B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.